Cel Sci (CVM) Income towards Parent Company (2010 - 2026)
Cel Sci (CVM) posted Income towards Parent Company of -$13.0 million for Q1 2026, down 134.11% sequentially from -$5.5 million in Q4 2025, and down 97.11% YoY from -$447.6 million in Q1 2025.
Cel Sci (CVM) Income towards Parent Company (2010 - 2026) Analysis & Trends
Cel Sci has reported Income towards Parent Company for 17 years, with the latest figure at -$13.0 million in Q1 2026.
- Quarterly Income towards Parent Company fell 97.11% year-over-year to -$13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.6 million (down 52.22% YoY) and the FY2025 annual result came in at -$90.7 million, down 2.09% from the prior year.
- Income towards Parent Company retreated to -$13.0 million in Q1 2026 per CVM's latest filing, from -$5.5 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$5.5 million in Q4 2025 and troughed at -$15.2 million in Q2 2025.
- A 5-year average of -$8.5 million and a median of -$7.9 million in 2025 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 22.08% in 2025, down 102.5% in 2025.
- Over 5 years, Income towards Parent Company stood at -$8.0 million in 2022, then increased by 16.39% to -$6.7 million in 2023, then fell by 5.84% to -$7.1 million in 2024, then climbed by 22.08% to -$5.5 million in 2025, then sank by 134.11% to -$13.0 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$13.0 million, -$5.5 million, and -$7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.95 Mn |
| Dec 31, 2025 | -5.53 Mn |
| Sep 30, 2025 | -7.92 Mn |
| Jun 30, 2025 | -15.22 Mn |
| Mar 31, 2025 | -6.57 Mn |
| Dec 31, 2024 | -7.10 Mn |
| Sep 30, 2024 | -6.16 Mn |
| Jun 30, 2024 | -7.52 Mn |
| Mar 31, 2024 | -7.24 Mn |
| Dec 31, 2023 | -6.71 Mn |
| Sep 30, 2023 | -7.63 Mn |
| Jun 30, 2023 | -8.37 Mn |
| Mar 31, 2023 | -8.34 Mn |
| Dec 31, 2022 | -8.03 Mn |
| Sep 30, 2022 | -9.10 Mn |
| Jun 30, 2022 | -9.93 Mn |
| Mar 31, 2022 | -9.82 Mn |
| Dec 31, 2021 | -9.13 Mn |
| Sep 30, 2021 | -8.60 Mn |
| Jun 30, 2021 | -10.48 Mn |